1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Recent Biotech Funding, Deals and Partnerships

Recent Biotech Funding, Deals and Partnerships

  • May 2014
  • -
  • Kalorama Information
  • -
  • 156 pages

Nearly one out of every 8 dollars invested in companies are invested in biotech. Biotech investment has increased significantly in the past few years, and 2013 saw a notable spike. In the last few years, this has resulted in a complex series of deals and transactions, ranging from complete buyouts, to licensing transactions, to a variety of collaborative arrangements. In addition to this influx of corporate capital, biotechnology companies have seen a significant influx of venture capital, as investors invest in new science and technology that they believe have potential in the clinic.

This Kalorama Information report, Recent Biotech Funding Deals and Partnerships, attempts to provide clarity on the phenomenon. The report analyzes the recent, current and potential landscape for investing in the biotechnology sector.

Included in the report's coverage are the following data points

56 Key Biotech Deals Analyzed: Financial Details and Therapeutic Potential
Venture Capital Dollar Trends, Overall Dollars Invested 2009-2013 (in US billions)
Health Care as a Percentage of Total Venture Investment, 2009-2012 (in US billions)
Biotech Companies Raising Series A Dollars, 2009-2012, Greater than $2 Million
Number of Biotech Series A Companies by Indication Oncology,
Platform Discovery, Diagnostics, CNS, Autoimmune)
Biotech Total Deal Value, 2005-2012
IPO Statistics
Personalized Medicine Disclosed M&A Number of Deals by Focus, 2010-2013

Analyzed are both venture and corporate capital funding efforts. In addition, the report looks at other collaborative approaches, including licensing, joint ventures and partnerships aimed at moving product candidates into the market place as approved therapies, especially if they address unmet medical needs.

This report also reviews the nature and direction of funding trends, and reviews the important role that investments play in moving technology into the market place. The report profiles several biotechnology sector companies and the deals that they were involved in from 2011 to 2014. Some of the companies and transactions profiled in the report include: Alkermes, Boston Biomedical, Dicerna Pharmaceuticals, immatics biotechnologies, Micromet, Reata Pharmaceuticals, UCB and Xoma.

The information presented in this report is the result of data gathered from company product literature and other corporate brochures and documents, as well as information found in the scientific and trade press. In addition, interviews were conducted with executives and analysts.

Table Of Contents

Recent Biotech Funding, Deals and Partnerships
1.0 EXECUTIVE SUMMARY
1.1 Key Findings
1.2 Methodology
2.0 INTRODUCTION
2.1 Reason for the Report
2.1.1 Why Investing Is Important
2.1.2 Beyond the Seed Stage
2.1.3 Identify Value Drivers
3.0 TRENDS AND EXPECTATIONS
3.1 Corporate Venture Capital Spurs MandA Activity
3.2 Licensing Deals to Grow
3.3 Venture Capital's Strong Outlook
3.4 Therapeutic Areas of Focus
3.4.1 The Outcomes Push
3.5 In Need of New Strategies
3.5.1 Modeling Potential Success
3.5.2 Crowdfunding
3.5.2.1 A Lifeline
4.0 GROWTH THROUGH SOPHISTICATED COLLABORATIONS
4.1 Determining Product Value
4.1.1 Quantifiable Issues
4.1.2 Revolutionary Value
4.1.3 Global Value
4.2 Changing Roles and Market Landscapes
5.0 VENTURE CAPITAL VS. CORPORATE CAPITAL
5.1 New Fundraising Vistas
5.2 Venture Arms with a Strategy
5.3 Corporate Capital Fundamentals
6.0 INVESTMENT DOLLAR TRENDS
6.1 Annual Numbers
6.1.1 Trends in 2013
6.1.2 Trends in 2012
6.1.3 Trends in 2011
6.1.4 Trends in 2010
6.1.5 Trends in 2009
6.2 Personalized Medicine
7.0 KEY DEALS
7.1 Ablynx NV
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.2 Acetylon Pharmaceuticals Inc.
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.3 AC Immune SA
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.4 Adimab
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.5 Aileron Therapeutics Inc.
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.6 Algeta ASA
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.7 Alios BioPharma Inc.
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.8 Alkermes
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.9 Alnylam Pharmaceuticals
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.10 Amylin Pharmaceuticals
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.11 Ardea Biosciences
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.12 Atara Biotherapeutics
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.13 Avila Therapeutics
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.14 Boston Biomedical
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.15 Cellectis
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.16 Clarus Ventures
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.17 CoStim Pharmaceuticals
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.18 Covagen AG
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.19 Dicerna Pharmaceuticals Inc.
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.20 Editas Medicine
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.21 Enanta Pharmaceuticals Inc.
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.22 Endocyte Inc.
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.23 Evotec AG
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.24 Forma Therapeutics
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.25 Galapagos NV
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.26 Gemin X Pharmaceuticals
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.27 Genmab
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.28 GlaxoSmithKline
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.29 Human Genome Sciences
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.30 immatics Biotechnologies GmbH
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.31 Inhibitex
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.32 Inhibrx
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.33 Isis Pharmaceuticals Inc.
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.34 Juno Therapeutics
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.35 Macrogenics Inc.
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.36 Mannkind Corp.
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.37 Medigene AG
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.38 Melinta Therapeutics
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.39 Merck
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.40 Mesoblast Ltd.
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.41 Micromet AG
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.42 Moderna Therapeutics Inc.
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.43 OncoMed Pharmaceuticals Inc.
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.44 Onyx Pharmaceuticals Inc.
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.45 Otonomy Inc.
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.46 Pharmasset
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.47 Plexxikon Inc.
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.48 Reata Pharmaceuticals
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.49 Royalty Pharma
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.50 Seattle Genetics Inc.
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.51 Sutro Biopharma Inc.
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.52 Thesan Pharmaceuticals Inc.
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.53 UCB Inc.
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.54 Voyager Therapeutics
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.55 Xenon Pharmaceuticals Inc.
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.56 Xoma Corp.
Description of Deal
Size
Agreement Type
Details
LIST OF EXHIBITS
1.0 EXECUTIVE SUMMARY
Summary Exhibit: Biotechnology Investment Dollars, 2012 and 2013 ($ millions)
6.0 INVESTMENT DOLLAR TRENDS
Exhibit 1: Venture Capital Dollar Trends, Overall Dollars Invested 2009-2013
Exhibit 2: Venture Capital Dollar Trends, Overall Dollars Invested 2009-2013
Exhibit 3: Venture Capital Dollar Trends, Biotechnology Dollars Invested 2009-2013
Exhibit 4: Venture Capital Dollar Trends, Biotechnology Dollars Invested 2009-2013
Exhibit 5: Breakdown of Overall and Biotech Venture Capital Dollars, Billions of Dollars US Invested in 2013
Exhibit 6: Venture Capital Dollar Trends, Biotechnology Dollars Invested by Quarter, 2009-2013
Exhibit 7: Health Care as a Percentage of Total Venture Investment, 2009-2012
Exhibit 8: Biotech Companies Raising Series A Dollars, 2009-2012, Greater than $2 Million
Exhibit 9: Number of Biotech Series A Companies by Indication, 2009, Raising More than $2 Million
Exhibit 10: Number of Biotech Series A Companies by Indication, 2010, Raising More Than $2 Million
Exhibit 11: Number of Biotech Series A Companies by Indication, 2011, Raising More Than $2 Million
Exhibit 12: Number of Biotech Series A Companies by Indication, 2012, Raising More Than $2 Million
Exhibit 13: Biotech Total Deal Value, 2005-2012, Minimum Two Big Exits
Exhibit 14: Personalized Medicine MandA with Disclosed Values, 2010-2013
Exhibit 15: Personalized Medicine Disclosed MandA Number of Deals by Focus, 2010-2013
Exhibit 16: Personalized Medicine Disclosed MandA Deal Value by Focus, 2010-2013
Exhibit 17: Personalized Medicine Financings, 2010-2013
Exhibit 18: Personalized Medicine Financings by Type, Number of Deals, 2010-2013
Exhibit 19: Personalized Medicine Financings by Category, Number of Deals, 2010-2013


View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025 Summary Atrial fibrillation (AF) is the most common cardiac arrhythmia and is a heart condition that causes an irregula ...

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025 Summary Venous thromboembolism (VTE) is a disease that includes a myriad of life-threatening disorders ranging from ...

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

Ulcerative Colitis: Kol Insight

September 2016 $ 8085

Hepatitis C: Kol Insight

September 2016 $ 8085

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.